Search
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • NASH
    • IBD
    • Publications
  • Patients
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      • Sec Filings
    • Investor Resources
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact
Publications
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • NASH
    • IBD
    • Publications
  • Patients
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      • Sec Filings
    • Investor Resources
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact
Publications

Sustained FXR agonist M480 shows superior efficacy to THRb agonist MGL-3196 in reversing NASH and advanced fibrosis

Back
Poster Presentation at AASLD Liver Meeting, November 2019

poster thumbnail

Download PDF

© 2021 Metacrine   |   3985 Sorrento Valley Blvd., Suite C, San Diego, CA 92121
  • Our Company
    ▼
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    ▼
    • Pipeline
    • NASH
    • IBD
    • Publications
  • Patients
  • Investors
    ▼
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      ▼
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      ▼
      • Sec Filings
    • Investor Resources
      ▼
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact